Humasys Co., Ltd. (205470)
Market Open
10 Aug, 06:30
KRX SM KRX SM Primary ₩
2,455. 00
+160
+6.9717%
₩
136.46B Market Cap
- P/E Ratio
- Div Yield
126,549 Volume
- Eps
₩ 2,295
Previous Close Want to track 205470 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
205470 trading today higher at ₩2,455, an increase of 6.9717% from yesterday's close, completing a monthly increase of 2.935% or ₩70. Over the past 12 months, 205470 stock gained 144.0358%.
205470 is not paying dividends to its shareholders.
Humasys Co., Ltd. has completed 4 stock splits, with the recent split occurring on May 08, 2026.
The company's stock is traded on one exchange.
Humasys Co., Ltd. (205470) FAQ
What is the stock price today?
The current price is ₩2,455.00.
On which exchange is it traded?
Humasys Co., Ltd. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 205470.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 136.46B.
Has Humasys Co., Ltd. ever had a stock split?
Humasys Co., Ltd. had 4 splits and the recent split was on May 08, 2026.
Humasys Co., Ltd. Profile
| Health Care Technology Industry | Healthcare Sector | - CEO | KRX SM Exchange | KR7205470008 ISIN |
| South Korea Country | 69 Employees | - Last Dividend | 8 May 2026 Last Split | - IPO Date |
Overview
Humasis Co. Ltd., established in 2000 and based in Anyang-si, South Korea, operates in the global health sector, especially focusing on the manufacturing and distribution of pharmaceuticals and medical devices. The company extends its reach both in South Korea and internationally, underscoring its commitment to advancing healthcare through innovation. Humasis has carved a niche for itself in the field of immunodiagnostics and biotechnology, offering a broad range of products that cater to various health needs and medical evaluations.
Products and Services
- Immunodiagnostic Kits: These kits include both quantitative and qualitative tests that cover a wide array of health conditions and concerns. Their applications extend to cardiac and cancer markers, detection of infectious diseases, hormonal imbalances, and aspects of women's health. This range provides crucial tools for early and accurate diagnosis, enhancing treatment outcomes.
- Bio-material Products:
- COVID-19 nucleocapsid protein and surface proteins from the human immunodeficiency virus (HIV), essential for research and diagnostic development.
- COVID-19 RT-PCR kit and COVID-19 Variant RT-qPCR kit, offering precise detection of SARS-CoV-2 and its variants.
- MPXV real-time PCR kit, designed for the qualitative detection of Monkeypox virus nucleic acids, addressing emerging global health threats.
- Diagnostic Equipment: The company's portfolio includes a variety of diagnostic tools such as urinalysis devices, blood glucose meters, and immunodiagnostics equipment. These products play a vital role in continuous monitoring and management of health conditions, supporting both patients and healthcare providers.
- Other Test Kits:
- Cotinine Test Kits for the detection of cotinine in urine, which is an indicator of tobacco use or exposure to nicotine. This test is critical for smoking cessation programs and health insurance assessments.
- G6PD Test Kits, an in vitro diagnostic tool for detecting glucose-6-phosphate dehydrogenase levels in human whole blood. This test is crucial for diagnosing G6PD deficiency, which can lead to hemolytic anemia in response to certain medications, infections, or other stressors.
Contact Information
Address: Hogye-dong, Shinwon Vision Tower
Phone: 82 31 8085 6200
Website: https://www.humasis.com
